The CEO/CFO sales are likely liquidity-driven following option exercises, not a bearish signal on fundamentals given the modest proportion of market cap. However, the cluster of three insiders selling within a week — including the CEO and CFO — adds mild caution. Monitor for any pipeline news (e.g., AXS-07, AXS-12, solriamfetol updates) that could explain the timing. The historical win rate on AXSM reports is high (88% T+20), but this cluster alone does not justify a directional bet.
Price Chart
Executive Summary
CEO Herriot and CFO Pizzie exercised stock options and immediately sold the resulting shares in open-market transactions on June 9, 2026, generating ~$19.9M in total proceeds. Director Coleman also sold $1.24M on June 2. The cluster is entirely sell-side with $21.1M in open-market sales, representing ~0.17% of AXSM's $12.1B market cap — a modest but notable amount. The CEO/CFO sales follow option exercises and are likely tax/planning driven, but the timing ahead of potential catalysts (e.g., pipeline updates) warrants monitoring.
Key Financial Metrics
Key Facts
- CEO Herriot sold 49,670 shares at ~$241.01 for ~$12.0M on June 9, 2026
- CFO Pizzie sold 33,000 shares at ~$240.09 for ~$7.9M on June 9, 2026
- Both CEO and CFO exercised options at $0-$4.95 cost basis before selling — no net cash outlay for the shares
- Director Coleman sold 5,500 shares at $223.39 for ~$1.24M on June 2, 2026
- Total open-market sales: ~$21.1M, or ~0.17% of AXSM's $12.1B market cap
- Two directors received non-cash grants of 1,721 shares each on June 5, 2026 — no economic signal
- AXSM has 93% analyst bullish consensus (25 Buy/Strong Buy, 2 Hold)
Financial Impact
Total insider sales of ~$21.1M represent ~0.17% of market cap — modest but notable for a biotech with significant pipeline value
Risk Factors
- CEO/CFO selling after option exercises could signal reduced conviction ahead of pipeline milestones
- Director Coleman's sale at a lower price ($223.39) vs. CEO/CFO ($240-241) suggests no coordinated bearish view
- Biotech sector volatility could amplify any negative read-through from insider sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-AXSM-1781039864729 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $179.25 (−16.50%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $179.25 (−18.85%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $179.25 (−18.85%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $179.25 (−24.54%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $179.25 (−28.00%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $179.25 (−28.23%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $179.25 (−26.63%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $179.25 (−29.26%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $179.25 (−29.75%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $179.25 (−29.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access